AstraZeneca's sBLA for IMFINZI plus enfortumab vedotin in muscle-invasive bladder cancer has been accepted and granted Priority Review by the FDA. The decision is based on the VOLGA Phase III trial showing statistically significant improvements in event-free survival and overall survival. The PDUFA date is Q4 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
